Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 10, Pages 2801
Publisher
MDPI AG
Online
2020-09-29
DOI
10.3390/cancers12102801
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products
- (2020) Keke Li et al. Cancer Cell International
- Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study
- (2020) Sanne Huijberts et al. Future Oncology
- Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications
- (2020) Wei Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy
- (2020) Magdalena Olbryt et al. Targeted Oncology
- A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
- (2020) Yangzi Tian et al. MEDICAL SCIENCE MONITOR
- Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma
- (2020) Mohamad Krayem et al. Cancers
- Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
- (2020) Mariusz L. Hartman et al. Cells
- Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition
- (2020) Florencia Madorsky Rowdo et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- BRAF inhibition curtails IFN‐gamma‐inducible PD‐L1 expression and upregulates the immunoregulatory protein galectin‐1 in melanoma cells
- (2020) Patryk Górniak et al. Molecular Oncology
- Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R
- (2020) Suresh Bugide et al. Oncogenesis
- Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis
- (2020) Marion Vanneste et al. Frontiers in Oncology
- BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
- (2020) Ilaria Proietti et al. Cancers
- Current State of Target Treatment in BRAF Mutated Melanoma
- (2020) Enrica Teresa Tanda et al. Frontiers in Molecular Biosciences
- A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors
- (2019) Baptiste Louveau et al. Oncotarget
- Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway
- (2019) Romi Gupta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data
- (2019) Ashley M. Hopkins et al. Pigment Cell & Melanoma Research
- An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells
- (2019) Valentina Perotti et al. ONCOGENE
- Quantitative proteomics links the intermediate filament nestin to resistance to targeted BRAF inhibition in melanoma cells
- (2019) Marisa Schmitt et al. MOLECULAR & CELLULAR PROTEOMICS
- Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells
- (2019) István Szász et al. MELANOMA RESEARCH
- BRAF targeting sensitizes resistant melanoma to cytotoxic T cells
- (2019) Cigdem Atay et al. CLINICAL CANCER RESEARCH
- Resistance to MAPK inhibitors in melanoma involves activation of the IGF-1R-MEK5-Erk5 pathway
- (2019) Lucía Benito-Jardón et al. CANCER RESEARCH
- 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes
- (2019) Aleksandra Mielczarek-Lewandowska et al. APOPTOSIS
- HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
- (2019) Michael F. Emmons et al. CANCER RESEARCH
- Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
- (2019) Ghanbar Mahmoodi Chalbatani et al. International Journal of Nanomedicine
- RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance
- (2019) Daniël A. Lionarons et al. CANCER CELL
- miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
- (2019) Simona Caporali et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma
- (2019) Ileine M Sanchez et al. MOLECULAR CANCER THERAPEUTICS
- Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities
- (2019) Jean-Philippe Coppé et al. NATURE CELL BIOLOGY
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy
- (2019) Francesca Consoli et al. PLoS One
- Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance
- (2019) Shun Li et al. Nature Communications
- Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance
- (2019) Yapeng Su et al. PLoS Computational Biology
- Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
- (2019) Malgorzata Czyz et al. Journal of Oncology
- Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma
- (2019) Charlotte R. Feddersen et al. CANCER RESEARCH
- A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
- (2019) Andrea Aloia et al. CLINICAL CANCER RESEARCH
- Upregulation of S100A9 contributes to the acquired resistance to BRAF inhibitors
- (2019) Sung-Hee Hwang et al. Genes & Genomics
- Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro
- (2019) Marta Osrodek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression
- (2019) Eszter Molnár et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The role of polo‐like kinase 3 in the response of BRAF‐mutant cells to targeted anticancer therapies
- (2019) Mahamat Babagana et al. MOLECULAR CARCINOGENESIS
- ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
- (2019) Ciro Francesco Ruggiero et al. Cancers
- EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma
- (2019) Yige Fu et al. Pharmaceutics
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) O Michielin et al. ANNALS OF ONCOLOGY
- NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth
- (2019) Tamer S. Kaoud et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
- (2019) Maria Grazia Atzori et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma
- (2019) Xiao Liu et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells
- (2019) S. A. Misek et al. ONCOGENE
- Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
- (2019) Matthew J. Sale et al. Nature Communications
- Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
- (2019) Hamid et al. Cancers
- A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model
- (2019) Lydia Bellmann et al. INTERNATIONAL JOURNAL OF CANCER
- T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma
- (2019) Carla Barceló et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma
- (2018) Ming-zhao Gao et al. ACTA PHARMACOLOGICA SINICA
- Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma
- (2018) Helma Zecena et al. BMC Systems Biology
- An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
- (2018) Liqin Wang et al. CELL
- Combined BRAF and HSP90 inhibition in patients with unresectableBRAFV600E mutant melanoma
- (2018) Zeynep Eroglu et al. CLINICAL CANCER RESEARCH
- SOX2-mediated upregulation of CD24 promotes adaptive resistance towards targeted therapy in melanoma
- (2018) Laura Hüser et al. INTERNATIONAL JOURNAL OF CANCER
- Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
- (2018) Claire A. Martin et al. INTERNATIONAL JOURNAL OF CANCER
- BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
- (2018) Jan Dörrie et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of BRAFV600E Cellular Localization in Melanoma
- (2018) Zakaria Y. Abd Elmageed et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Identification and functional analysis of SOX10 phosphorylation sites in melanoma
- (2018) Julia C. Cronin et al. PLoS One
- miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP
- (2018) Min Ho Choe et al. Cell Death & Disease
- Dual suppression of inner and outer mitochondrial membrane functions augments apoptotic responses to oncogenic MAPK inhibition
- (2018) Madhavika N. Serasinghe et al. Cell Death & Disease
- RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
- (2018) Fu Xi Lei et al. Cell Death & Disease
- Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy
- (2018) Ali Talebi et al. Nature Communications
- In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
- (2018) Jessica L.F. Teh et al. Cancer Discovery
- YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
- (2018) Min Hwan Kim et al. Cancer Immunology Research
- Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells
- (2018) Karin Kfir-Elirachman et al. NEOPLASIA
- Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment
- (2018) Natalia Pieper et al. OncoImmunology
- The Epithelial-to-Mesenchymal Transition in Cancer
- (2018) Joëlle Roche Cancers
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
- (2018) Luigi Fattore et al. CELL DEATH AND DIFFERENTIATION
- Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600–mutant metastatic melanoma
- (2018) Guy Ben-Betzalel et al. EUROPEAN JOURNAL OF CANCER
- Acquisition of resistance to vemurafenib leads to interleukin-10 production through an aberrant activation of Akt in a melanoma cell line
- (2018) Takashi Inozume et al. JOURNAL OF DERMATOLOGY
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Codon-specific translation reprogramming promotes resistance to targeted therapy
- (2018) Francesca Rapino et al. NATURE
- SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
- (2018) Thomas Strub et al. Nature Communications
- Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma
- (2018) Axel Hauschild et al. JAMA Oncology
- Microneedle-Assisted Topical Delivery of Photodynamically Active Mesoporous Formulation for Combination Therapy of Deep-Seated Melanoma
- (2018) Huijun Phoebe Tham et al. ACS Nano
- Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells
- (2018) Oxana Ryabaya et al. BIOMEDICINE & PHARMACOTHERAPY
- Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq Analysis
- (2018) Jun-Ho Ahn et al. Biomolecules & Therapeutics
- Targeting the sphingosine 1-phosphate axis exerts potent antitumor activity in BRAFi-resistant melanomas
- (2018) David Garandeau et al. MOLECULAR CANCER THERAPEUTICS
- KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations
- (2018) Xiaoni Liu et al. MOLECULAR CANCER THERAPEUTICS
- Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells
- (2018) Purusottam Mohapatra et al. Molecular Oncology
- Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer
- (2018) Nicholas Theodosakis et al. Pigment Cell & Melanoma Research
- Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma
- (2018) Sébastien Corre et al. Nature Communications
- Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas
- (2018) James L. Figarola et al. Oncotarget
- Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types
- (2018) Allison R. Greenplate et al. Cancer Immunology Research
- Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma
- (2018) Christina Brummer et al. CANCER LETTERS
- HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
- (2017) Stuart J. Gallagher et al. INTERNATIONAL JOURNAL OF CANCER
- p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis
- (2017) Nicholas Theodosakis et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma
- (2017) Valentina Audrito et al. JNCI-Journal of the National Cancer Institute
- Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF V600 -mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
- (2017) Max Schreuer et al. LANCET ONCOLOGY
- Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells
- (2017) Joel Basken et al. MOLECULAR & CELLULAR PROTEOMICS
- A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
- (2017) Stefanie Galbán et al. MOLECULAR CANCER THERAPEUTICS
- P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells
- (2017) Mahamat Babagana et al. MOLECULAR CARCINOGENESIS
- Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood
- (2017) Julia Joung et al. NATURE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma
- (2017) A Jain et al. ONCOGENE
- Phenotype characterization of human melanoma cells resistant to dabrafenib
- (2017) Fabiola Gilda Cordaro et al. ONCOLOGY REPORTS
- Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance
- (2017) Lu Wang et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
- (2017) Alireza Azimi et al. Cell Death & Disease
- Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation
- (2017) Chunying Song et al. Cancer Discovery
- Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma
- (2017) Renier Heijkants et al. Oncotarget
- Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells
- (2017) Matthew L. Fisher et al. Oncotarget
- mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition
- (2017) Gongda Xue et al. Oncotarget
- MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
- (2017) Sean Caenepeel et al. Oncotarget
- Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
- (2017) Corinna Kosnopfel et al. Oncotarget
- BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
- (2017) Fen Liu et al. Oncotarget
- The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
- (2017) Laurence Booth et al. Oncotarget
- Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
- (2017) Jae-Hyeon Kim et al. Cancer Research and Treatment
- Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence
- (2017) Katherine R. Singleton et al. Cell Reports
- Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma
- (2017) Valentina Audrito et al. JNCI-Journal of the National Cancer Institute
- Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition
- (2017) Marylise Fernandez et al. Cancer Medicine
- Suppression of B-RafV600E melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone
- (2016) Seung-Keun Hong et al. CANCER BIOLOGY & THERAPY
- HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors
- (2016) A. Budina-Kolomets et al. CANCER RESEARCH
- Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance
- (2016) M. P. Smith et al. CLINICAL CANCER RESEARCH
- CEACAM1: Expression and Role in Melanocyte Transformation
- (2016) Gabriela Turcu et al. DISEASE MARKERS
- ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
- (2016) Geoffrey Richard et al. EMBO Molecular Medicine
- p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
- (2016) Mohammad Krayem et al. EUROPEAN JOURNAL OF CANCER
- GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax
- (2016) Kateřina Vlčková et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma
- (2016) Fanny Matheis et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition
- (2016) Ritin Sharma et al. JOURNAL OF PROTEOME RESEARCH
- IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples
- (2016) Jennifer Hintzsche et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
- (2016) Jurjen Tel et al. Journal of Translational Medicine
- Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells
- (2016) Mary JC Hendrix et al. LABORATORY INVESTIGATION
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
- (2016) Georgina V Long et al. LANCET ONCOLOGY
- Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/ BRAF -Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor
- (2016) Hélène Bonnevaux et al. MOLECULAR CANCER THERAPEUTICS
- The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas
- (2016) J. Peh et al. MOLECULAR CANCER THERAPEUTICS
- Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation
- (2016) Min Pan et al. NATURE CELL BIOLOGY
- Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
- (2016) Che-Hung Shen et al. NATURE MEDICINE
- Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib
- (2016) N A Doudican et al. ONCOGENE
- ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation
- (2016) Ueihuei Peng et al. ONCOLOGY REPORTS
- miR-579-3p controls melanoma progression and resistance to target therapy
- (2016) Luigi Fattore et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High-resolution interrogation of functional elements in the noncoding genome
- (2016) N. E. Sanjana et al. SCIENCE
- Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells
- (2016) G Pathria et al. Cell Death & Disease
- Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
- (2016) M. A. Miller et al. Cancer Discovery
- miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways
- (2016) Xiaoyan Sun et al. Oncotarget
- Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
- (2016) Kotryna Seip et al. Oncotarget
- Mitochondrial oxidative phosphorylation controls cancer cell’s life and death decisions upon exposure to MAPK inhibitors
- (2016) Paola Corazao-Rozas et al. Oncotarget
- The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma
- (2016) Rajeev K. Boregowda et al. Oncotarget
- Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity
- (2016) Charles H. Adelmann et al. Oncotarget
- A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib
- (2016) Tobias Sinnberg et al. EBioMedicine
- JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
- (2016) Bjoern Titz et al. Cell Discovery
- A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib
- (2015) Grazia Graziani et al. BIOCHEMICAL PHARMACOLOGY
- Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data
- (2015) O. Abdel-Rahman et al. Clinical & Translational Oncology
- Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
- (2015) C. Krepler et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
- (2015) T. Wang et al. CLINICAL CANCER RESEARCH
- Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation
- (2015) M. H. Kim et al. EMBO JOURNAL
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
- (2015) Douglas B. Johnson et al. EUROPEAN JOURNAL OF CANCER
- HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors
- (2015) Rosa Sottile et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- BRAF and MEK Inhibition Variably Affect GD2-specific Chimeric Antigen Receptor (CAR) T-Cell Function In Vitro
- (2015) Tessa Gargett et al. JOURNAL OF IMMUNOTHERAPY
- The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma
- (2015) Yao Zhan et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
- (2015) Jinhua Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- MITF Modulates Therapeutic Resistance through EGFR Signaling
- (2015) Zhenyu Ji et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
- (2015) S. R. Whittaker et al. MOLECULAR CANCER THERAPEUTICS
- The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression
- (2015) M. S. Phadke et al. MOLECULAR CANCER THERAPEUTICS
- Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
- (2015) Franziska Baenke et al. Molecular Oncology
- Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
- (2015) Silvana Konermann et al. NATURE
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detailed imaging and genetic analysis reveal a secondaryBRAFL505Hresistance mutation and extensive intrapatient heterogeneity in metastaticBRAFmutant melanoma patients treated with vemurafenib
- (2015) Marlous Hoogstraat et al. Pigment Cell & Melanoma Research
- PTEN regulates IGF-1R-mediated therapy resistance in melanoma
- (2015) Jun Wang et al. Pigment Cell & Melanoma Research
- The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth ofBRAF-mutant melanoma cells in combination with other signaling pathway inhibitors
- (2015) Casey G. Langdon et al. Pigment Cell & Melanoma Research
- miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment
- (2015) Shujing Liu et al. Pigment Cell & Melanoma Research
- BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
- (2015) Daniele Perna et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
- (2015) Rachel Ramsdale et al. Science Signaling
- Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing
- (2015) Maayan Salton et al. Nature Communications
- Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
- (2015) Neel M. Fofaria et al. Oncotarget
- Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
- (2015) Luigi Fattore et al. Oncotarget
- The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors
- (2015) Audrey Delmas et al. Oncotarget
- A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification
- (2015) Matteo Dugo et al. Oncotarget
- Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
- (2015) Devin G. Roller et al. Oncotarget
- miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma
- (2015) Mitchell S. Stark et al. Oncotarget
- Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation
- (2015) Hyungsoo Kim et al. Cell Reports
- The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
- (2015) Rachel Ramsdale et al. Science Signaling
- Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib
- (2015) Abdelali Lehraiki et al. Cell Discovery
- Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma
- (2015) Robert Parker et al. Frontiers in Oncology
- Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
- (2015) Melanie Sweetlove et al. Frontiers in Oncology
- Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3
- (2015) Jennifer M. Atkinson et al. PLoS One
- Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs
- (2015) Joost C. M. Uitdehaag et al. PLoS One
- Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
- (2015) Kavitha Gowrishankar et al. PLoS One
- Mitochondrial oxidative stress is the achille’s heel of melanoma cells resistant to Braf-mutant inhibitor
- (2015) Paola Corazao-Rozas et al. Oncotarget
- PDGFRα up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
- (2015) Francesco Sabbatino et al. Oncotarget
- Protein Kinase Cδ Is a Therapeutic Target in Malignant Melanoma with NRAS Mutation
- (2014) Asami Takashima et al. ACS Chemical Biology
- Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor
- (2014) C. H. Kugel et al. CANCER RESEARCH
- The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
- (2014) Ian R. Watson et al. CANCER RESEARCH
- Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation
- (2014) Nora Pencheva et al. CELL
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- (2014) M. Atefi et al. CLINICAL CANCER RESEARCH
- Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
- (2014) M. S. Carlino et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer
- (2014) G. L. Johnson et al. CLINICAL CANCER RESEARCH
- 67-kDa Laminin Receptor-dependent Protein Phosphatase 2A (PP2A) Activation Elicits Melanoma-specific Antitumor Activity Overcoming Drug Resistance
- (2014) Shuntaro Tsukamoto et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mitogen-activated Protein Kinase (MAPK) Hyperactivation and Enhanced NRAS Expression Drive Acquired Vemurafenib Resistance in V600E BRAF Melanoma Cells
- (2014) Michael Lidsky et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
- (2014) Jamie N. Anastas et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
- (2014) Xiao-Hong Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib
- (2014) Huimin Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics
- (2014) Vito W. Rebecca et al. MOLECULAR & CELLULAR PROTEOMICS
- The siRNA-mediated downregulation of N-Ras sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors
- (2014) Jun-Ho Ahn et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
- (2014) Amanda Lassen et al. Molecular Cancer
- Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
- (2014) J. Acquaviva et al. MOLECULAR CANCER THERAPEUTICS
- MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
- (2014) J. Asundi et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models
- (2014) T. Smyth et al. MOLECULAR CANCER THERAPEUTICS
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
- (2014) Y. Narita et al. MOLECULAR CANCER THERAPEUTICS
- ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
- (2014) M. A. Smit et al. Molecular Systems Biology
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
- (2014) Lise Boussemart et al. NATURE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity
- (2014) P K Bajpe et al. ONCOGENE
- Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling
- (2014) Andy J. Chien et al. PLoS One
- Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics
- (2014) Dennie T. Frederick et al. PLoS One
- Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway
- (2014) Alexander Gross et al. Targeted Oncology
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
- (2014) Georgina V. Long et al. Nature Communications
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma
- (2014) Marian M. Deuker et al. Cancer Discovery
- The MEK1/2 Inhibitor AS703026 Circumvents Resistance to the BRAF Inhibitor PLX4032 in Human Malignant Melanoma Cells
- (2013) Seong Joon Park et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf
- (2013) Jun-Ho Ahn et al. Biomolecules & Therapeutics
- Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis
- (2013) Nicole Beauchemin et al. CANCER AND METASTASIS REVIEWS
- Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
- (2013) A. Nakamura et al. CANCER RESEARCH
- C-RAF Mutations Confer Resistance to RAF Inhibitors
- (2013) R. Antony et al. CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
- (2013) H. E. Haarberg et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma
- (2013) J. Wang et al. MOLECULAR CANCER THERAPEUTICS
- IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase–driven tumors
- (2013) Katherine L Jameson et al. NATURE MEDICINE
- Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor
- (2013) T M Becker et al. ONCOGENE
- Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain
- (2013) Timothy R. Wagenaar et al. Pigment Cell & Melanoma Research
- Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
- (2013) Xinqi Wu et al. PLoS One
- BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
- (2013) Rizwan Haq et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma
- (2013) W Hu et al. Cell Death & Disease
- A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
- (2013) H. Shi et al. Cancer Discovery
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- An Unholy Alliance: Cooperation between BRAF and NF1 in Melanoma Development and BRAF Inhibitor Resistance
- (2013) Geoffrey T. Gibney et al. Cancer Discovery
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
- (2013) Jessie Villanueva et al. Cell Reports
- How to Fool a Wonder Drug: Truncate and Dimerize
- (2012) Miriam Molina-Arcas et al. CANCER CELL
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
- (2012) Vipin Yadav et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
- (2012) Kavitha Gowrishankar et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma
- (2012) Wesley O. Greaves et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
- (2012) Sara A Byron et al. Molecular Cancer
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma
- (2012) Austin Y. Shull et al. PLoS One
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells
- (2011) Ling Yu et al. IMMUNOLOGIC RESEARCH
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- (2011) Mohammad Atefi et al. PLoS One
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- (2010) K H T Paraiso et al. BRITISH JOURNAL OF CANCER
- Rac and Rho GTPases in cancer cell motility control
- (2010) Matteo Parri et al. Cell Communication and Signaling
- Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
- (2010) Jill C Rubinstein et al. Journal of Translational Medicine
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started